IL320785A - נוגדנים בי-ספציפיים ציטוטוקסיים הנקשרים ל- dr5 ו muc16- ושימושים בהם - Google Patents

נוגדנים בי-ספציפיים ציטוטוקסיים הנקשרים ל- dr5 ו muc16- ושימושים בהם

Info

Publication number
IL320785A
IL320785A IL320785A IL32078525A IL320785A IL 320785 A IL320785 A IL 320785A IL 320785 A IL320785 A IL 320785A IL 32078525 A IL32078525 A IL 32078525A IL 320785 A IL320785 A IL 320785A
Authority
IL
Israel
Prior art keywords
muc16
bispecific antibodies
antibodies binding
cytotoxic
cytotoxic bispecific
Prior art date
Application number
IL320785A
Other languages
English (en)
Original Assignee
Immuvia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuvia Inc filed Critical Immuvia Inc
Publication of IL320785A publication Critical patent/IL320785A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL320785A 2022-11-10 2025-05-08 נוגדנים בי-ספציפיים ציטוטוקסיים הנקשרים ל- dr5 ו muc16- ושימושים בהם IL320785A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263424323P 2022-11-10 2022-11-10
US202363443606P 2023-02-06 2023-02-06
PCT/US2023/079313 WO2024102962A1 (en) 2022-11-10 2023-11-10 Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof

Publications (1)

Publication Number Publication Date
IL320785A true IL320785A (he) 2025-07-01

Family

ID=89164186

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320785A IL320785A (he) 2022-11-10 2025-05-08 נוגדנים בי-ספציפיים ציטוטוקסיים הנקשרים ל- dr5 ו muc16- ושימושים בהם

Country Status (8)

Country Link
EP (1) EP4615874A1 (he)
JP (1) JP2025539040A (he)
KR (1) KR20250134582A (he)
CN (1) CN120584135A (he)
AU (1) AU2023375570A1 (he)
IL (1) IL320785A (he)
MX (1) MX2025005336A (he)
WO (1) WO2024102962A1 (he)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
PL2135881T3 (pl) 2005-06-20 2012-02-29 Genentech Inc Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
CA2773515C (en) 2009-09-29 2015-04-28 Roche Glycart Ag Bispecific death receptor agonistic antibodies
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP3360898A1 (en) * 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
EP3710482A4 (en) 2017-11-14 2021-08-18 University Of Virginia Patent Foundation COMPOSITIONS AND METHODS OF MANUFACTURING AND USING BISPECIFIC ANTIBODIES
EP3906055A4 (en) * 2019-01-04 2023-01-04 Trio Pharmaceuticals, Inc. MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES

Also Published As

Publication number Publication date
JP2025539040A (ja) 2025-12-03
AU2023375570A1 (en) 2025-06-12
MX2025005336A (es) 2025-10-01
CN120584135A (zh) 2025-09-02
KR20250134582A (ko) 2025-09-11
WO2024102962A1 (en) 2024-05-16
EP4615874A1 (en) 2025-09-17

Similar Documents

Publication Publication Date Title
IL288749A (he) נוגדני שרשרת כבדים רב-תכליתיים הנקשרים ל- cd22 ו- cd3
IL290230A (he) נוגדנים ביספציפיים טריוולנטיים הנקשרים לקלאודין 6 או קלאודין 18.2 ו– cd3 לטיפול במחלות סרטן מבטא קלאודין
SG10201900015XA (en) Bispecific cd33 and cd3 binding proteins
PH12020550933A1 (en) Antibodies binding ctla-4 and uses thereof
GB201912681D0 (en) Bispecific binding agent that binds to cd117/c-kit and cd3
MX2021014193A (es) Moleculas de enlace biespecificas anti-ror1/anti-cd3.
IL286634A (he) נוגדנים לפירוגלוטמט עמילואיד-בתא ושימושים בהם
CA3251582A1 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
AU2016210068A1 (en) Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123
MX2017015380A (es) Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33.
ZA202104356B (en) Monoclonal antibodies that bind specifically to human trbv9
IL304554A (he) קולטני אנטיגן כימריים ביספציפיים הנקשרים ל- cd19 ו- cd22
IL315438A (he) נוגדנים אנטי-cd3 חדשים ושימושים בהם
IL320903A (he) נוגדנים הנקשרים ל- c1s ושימושים בהם
IL320785A (he) נוגדנים בי-ספציפיים ציטוטוקסיים הנקשרים ל- dr5 ו muc16- ושימושים בהם
IL311805A (he) נוגדנים הנקשרים ל- cd30ו- cd3
CA3272592A1 (en) Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
EP3960762A4 (en) BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS IL-17A AND TNF-ALPHA
IL289497A (he) נוגדנים הטרודימריים הנקשרים ל-cd38 ול-cd3
SG11202107538VA (en) Formulations of antibodies that bind human cd137 and uses thereof
HK40115388A (en) Antibodies binding to cd30 and cd3
HK40107539A (en) Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3
IL326477A (he) נוגדן בעל דומיין יחיד הקושר cdcp1 באופן ספציפי ושימושיו
CA3301083A1 (en) Single-domain antibody specifically binding to cdcp1 and use thereof
IL325601A (he) נוגדנים הנקשרים ל-cd3